^
Association details:
| Biomarker: | CCR4 overexpression |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | tivumecirnon (FLX475) (CCR4 receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Title:
RAPT THERAPEUTICS REPORTS POSITIVE INITIAL DATA FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF FLX475 IN MULTIPLE CANCER INDICATIONS
Published date:
11/16/2020
Excerpt:
Checkpoint inhibitor-naïve head and neck cancer...Six patients initially treated with monotherapy crossed over to combination therapy, with one achieving a partial response and a second patient with an unconfirmed partial response (2/6).
